Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 39.84% | 19.81% | -8.77% | -31.22% | -8.84% |
| Total Depreciation and Amortization | -76.30% | -41.73% | 9.42% | 21.37% | 43.44% |
| Total Amortization of Deferred Charges | -18.75% | -12.50% | -6.25% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -73.54% | -64.08% | -45.38% | 98.99% | 728.14% |
| Change in Net Operating Assets | 292.08% | 69.21% | -113.80% | 148.46% | -2,233.62% |
| Cash from Operations | 30.68% | -13.81% | -65.79% | 50.27% | 30.21% |
| Capital Expenditure | 100.00% | 94.57% | 95.85% | 31.67% | -12.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 232.63% | 180.81% | 146.64% | 129.50% | -12.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -99.91% | -41.53% | 28.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -100.00% | -99.91% | -41.53% | 28.35% |
| Foreign Exchange rate Adjustments | -131.66% | 65.72% | 447.01% | -111.66% | 672.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.12% | -13.60% | -36.57% | 43.87% | 45.73% |